论文部分内容阅读
目的探究胺碘酮联合厄贝沙坦对心力衰竭合并心律失常的临床疗效。方法选取我院收治的146例心力衰竭合并心律失常患者,将其随机分成对照组和观察组,每组各73例。两组患者均给予胺碘酮治疗,在此治疗基础上,观察组患者联合厄贝沙坦进行治疗,观察并比较两组患者的临床治疗效果和心室射血分数改善情况。结果经过治疗,观察组患者的治疗总有效率(94.52%)高于对照组(79.45%);对照组患者心室射血分数为(32.51±2.01)%,低于观察组患者的(36.09±2.03)%,各数据比较差异具有统计学意义(P<0.05)。结论胺碘酮联合厄贝沙坦对心力衰竭合并心律失常患者的治疗具有显著疗效,值得临床推广应用。
Objective To investigate the clinical efficacy of amiodarone in combination with irbesartan in patients with heart failure and arrhythmia. Methods 146 patients with heart failure and arrhythmia admitted to our hospital were randomly divided into control group and observation group, with 73 cases in each group. Both groups were given amiodarone treatment, on the basis of this treatment, the observation group combined with irbesartan for treatment, observation and comparison of two groups of patients with clinical treatment and ventricular ejection fraction improved. Results After treatment, the total effective rate (94.52%) in the observation group was significantly higher than that in the control group (79.45%). The control group had a higher rate of ventricular ejection fraction (32.51 ± 2.01)%, lower than that of the observation group (36.09 ± 2.03) )%, The difference was statistically significant (P <0.05). Conclusions Amiodarone combined with irbesartan has a significant effect on the treatment of patients with heart failure and arrhythmia, which is worthy of clinical application.